Rubius Therapeutics Inc
NASDAQ:RUBY 3:59:51 PM EDT
Earnings Announcements
Rubius Therapeutics Reports First Quarter 2022 Financial Results
Published: 05/10/2022 12:27 GMT
Rubius Therapeutics Inc (RUBY) - Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update.
Q1 Loss per Share $0.58.
As of March 31, 2022, Cash, Cash Equivalents and Investments Were $176.5 Million, Compared to $225.8 Million As of Dec 31, 2021.
As of March 31, 2022, Cash, Cash Equivalents and Investments Provides Rubius With a Cash Runway Into Second Half of 2023.
Q1 Earnings per Share View $-0.58 -- Refinitiv Ibes Data (analyst estimates).
Q1 Loss per Share $0.58.
As of March 31, 2022, Cash, Cash Equivalents and Investments Were $176.5 Million, Compared to $225.8 Million As of Dec 31, 2021.
As of March 31, 2022, Cash, Cash Equivalents and Investments Provides Rubius With a Cash Runway Into Second Half of 2023.
Q1 Earnings per Share View $-0.58 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.55
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.55
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.55
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.55
More details on our Analysts Page.